Infographic on the Growth of Pharmaceutical Industry in India

The Indian pharmaceutical industry is projected to grow at a CAGR of over 10% to reach a size of US$ 130 billion by 2030.

Advantage India

Cost
Efficiency

* India has emerged as the medial tourism hub of the world providing cost-effective treatments with the latest technology enabled by several pathbreaking reforms and provisions in healthcare sector.

* Access to affordable HIV treatment from India is one of the greatest success stories in medicine. India is one of the biggest suppliers of low-cost vaccines in the world, thereby rightly making it the ‘Pharmacy of the World’.

Economic
Drivers

*According to Bain & Co, the Indian Pharmaceutical market stood at Rs. 4,71,295 crore (US$ 55 billion) in 2025 and is expected to grow to Rs. 10,28,280-11,13,970 crore (US$ 120-130 billion) by 2030.

*In FY24 domestic consumption was valued at Rs. 2,01,372 crore (US$ 23.5 billion).

*The pharmaceutical industry’s total turnover stood at Rs. 2,25,000 crore (US$ 26.26 billion) in FY25 lead by cardiac, gastrointestinal and anti-diabetic segments.

*India has the largest number of USFDA-compliant plants outside the US and over 2,000 WHO-GMP approved facilities, exporting to 150+ countries.

*CRDMO industry expected to double to Rs. 1,21,282 crore (US$ 14 billion) by 2028, reinforcing India’s role in global supply chains.

Policy
Support

*PLI scheme: Rs. 15,000 crore (US$ 2.04 billion) outlay (2020-21 to 2028-29) to boost manufacturing, investment, and product diversification.

*Strengthening of Pharmaceutical Industry (SPI): Rs. 500 crore (US$ 60.6 million) to support pharma clusters and MSMEs in productivity, quality, and sustainability.

*Under the Pradhan Mantri Bhartiya Janaushadhi Pariyojana, 16,912 Jan Aushadhi Kendras are operational as of June 30, 2025, with a target of 25,000 by March 2027, offering 2,110 medicines and 315 devices/consumables to promote affordable quality generic healthcare.

*Government disbursed Rs. 604 crore (US$ 69.76 million) under the PLI scheme in H1 FY25.

Increasing
Investment

*FDI policy: Up to 100% FDI allowed via automatic route for Greenfield pharma projects; up to 74% for Brownfield via automatic, beyond that with government approval.

*The Drugs & Pharmaceuticals sector received FDI inflow of Rs. 2,10,940 crore (US$ 24.62 billion) from April 2000-June 2025.

*Union Budget 2025-26: Allocation of Rs. 5,268 crore (US$ 602 million) for the Department of Pharmaceuticals, up 28.8% over previous budget estimates.

Snapshot Showcase Infographics Reports

Last updated: Oct, 2025

Related News

30 Dec 25

India's export to Australia grows 8% over 3 years of Ind-Aus ECTA...

India’s exports to Australia grew by 8% in FY25 under the India-Australia Economic Cooperation and Trade Agreement, with all tariff lines set to go zero-duty, boosting trade and market access across key sectors.

19 Dec 25

India's pharma exports cross US$ 30 billion: Commerce Secretary Mr. Rajesh Agrawal...

India’s pharmaceutical exports have crossed US$ 30 billion in value, driven by robust global demand for vaccines, generic medicines, and other therapeutic products, underscoring the country’s strong positioning in global healthcare supply chains.

8 Dec 25

Lupin gets USFDA nod for multiple sclerosis drug...

Lupin has received tentative USFDA approval to market generic Siponimod Tablets for treating multiple sclerosis, strengthening its US portfolio in speciality medicines.

27 Nov 25

CCRAS launches SIDDHI 2.0 to strengthen research-driven innovation in Ayurveda pharma sector...

CCRAS launched SIDDHI 2.0 to fast-track evidence-based Ayurveda innovation through stronger industry collaboration and streamlined research-to-product pathways.

25 Nov 25

Exports and domestic demand to drive steady growth for pharma SMEs in FY26...

India’s pharmaceutical sector is expected to see steady revenue growth in FY26, supported by stronger export demand and new product launches, with SME clusters sustaining healthy momentum.

Major states for Pharmaceuticals

Karnataka
Maharashtra
Gujarat
Uttar Pradesh
Delhi NCR
Tamil Nadu
Telangana

Industry Contacts

Posters

Pharmaceutical Companies in India

Indian pharma company have won around 40 per cent of all Abbreviated New Drug Approval (ANDA) from the US Food and Drug Administration (FDA) between january and july 2013.